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ABSTRACT 
Complex visual hallucinations occur in 70-80% of dementia with Lewy bodies (DLB) 
subjects and significantly affect wellbeing. Whilst the pathobiology of visual 
hallucinations in DLB remains poorly understood, several hypothetical models have 
suggested that visual attentional mechanisms may be altered, leading to a potential 
vulnerability to visual hallucinations. The present study investigated whether 
neuropathological changes occur in the pulvinar nucleus, a thalamic structure with a 
fundamental role in visual attention. Post-mortem pulvinar tissue was acquired from 
eight DLB, eight Alzheimer’s disease (AD) and eight control cases and analyzed 
using stereological and quantitative neuropathological techniques. Lewy body 
pathology was found in all pulvinar sub-regions in DLB cases. However, neuronal 
loss was specifically found in the lateral pulvinar of DLB cases compared to control 
cases. Although significant reductions in lateral neuron number were also found in 
AD cases compared to controls, these changes were not as marked as those 
observed in DLB cases. Previous studies have shown alterations to lateral areas of 
the pulvinar on neuroimaging, where they were found to be related to the frequency 
and severity of visual hallucinations. The lateral pulvinar is thought to modulate 
visual cortical activity based on attentional demands, thus contributing to visual 
attentional functioning. As alterations to visual attentional function and visual cortical 
activity have been postulated to contribute to visual hallucinations, the present 
results suggest neuropathological changes in visual components of the pulvinar that 
may contribute to attentional deficits and promote the manifestation of visual 
hallucinations in DLB.  
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INTRODUCTION 
Dementia with Lewy bodies (DLB) is the second most common form of primary 
neurodegenerative dementia after Alzheimer’s disease (AD) (1), accounting for 
approximately 4.2% of all dementia cases (2). Clinically, DLB is characterized by 
three core symptoms of fluctuating cognition, parkinsonism and visual hallucinations, 
in the presence of global cognitive decline (3).  
Visual hallucinations occur in 60-80% of DLB cases (4) and have been found to 
reduce patient quality of life (5, 6) and add to caregiver burden (7). Visual 
hallucinations in DLB are usually complex and recurrent, often involving animals, 
insects and/or disembodied faces (8). Visuo-perceptual deficits, including 
impairments in eye movements and complex visual functions, are also common (9).  
As perceptual abnormalities most frequently affect the visual domain, several studies 
have examined the visual system in DLB patients with the aim of assessing potential 
structural and physiological changes that give rise to these phenomena. Although 
the causative factors are unknown, several hypotheses share the idea that the 
specificity and distribution of pathological alterations may be critical for the elicitation 
of visual hallucinations in DLB (10-12). Therefore, the manifestation of visual 
hallucinations in DLB may be related to the degeneration of some regions, but also 
the relative preservation of others.   
Neuropathological studies of the retina in DLB have demonstrated abnormal 
proteinaceous inclusions (13) which may (14), or may not (15), be Lewy body-type 
pathology. Additionally, retinal nerve thinning (16) and electroretinogram 
abnormalities (17) have demonstrated potential functional changes in the retina in 
DLB. However, the lateral geniculate nucleus (LGN), the primary afferent visual relay 
structure between the retina and the primary visual cortex, is relatively spared in DLB 
compared to AD (18), suggesting that visual hallucinations in DLB may be facilitated 
by pathological changes in other parts of the visual system.  
In DLB patients with visual hallucinations, focusing attention upon the object of 
hallucination has been demonstrated to promote its cessation (19), implying that 
visual attention may play a role in this phenomenon. Perceptual changes resulting 
from altered visual attentional processes have been postulated to contribute a 
vulnerability to hallucination in DLB (12, 20).  The pulvinar nucleus of the thalamus 
plays a central role in visual attentional mechanisms (21, 22), and lesions to the 
pulvinar can cause deficits in filtering distracting stimuli (23) and feature binding of 
visual objects (24). The pulvinar has widespread cortical connections and is thought 
to play a general role in modulating cortico-cortical activity based on attentional 
demands (25). The pulvinar nucleus is traditionally parcellated into four anatomical 
sub-regions: anterior, medial, lateral and inferior (26). However, these histological 
sub-regions do not map perfectly onto sub-regions that have been segregated based 
on functionality or connectivity (27).  
Recent evidence has suggested that the pulvinar undergoes degeneration in DLB 
(28) and that DLB cases have reduced metabolism in the pulvinar (29). The degree 
of degeneration in sub-regions of the pulvinar, as assessed by mean diffusivity on 
fMRI, has been demonstrated to predict clinical markers of visual hallucination 
frequency and severity (28). Despite these findings, no previous neuropathological 
study has examined the sub-regions of the pulvinar in DLB in the context of visual 
hallucinations. However, one study did report Lewy body pathology in the pulvinar as 
a whole, as part of a wider study of the visual system (30). The present study 
therefore aimed to investigate the sub-regions of the pulvinar in post-mortem tissue 
taken from DLB cases that had experienced visual hallucinations during life to 
assess potential degenerative morphometric and/or neuropathological changes 
using unbiased stereological methods.        
 
  
METHODS AND MATERIALS 
Tissue preparation 
Human post-mortem tissue was obtained from the Newcastle Brain Tissue Resource 
(NBTR) and ethical approval was granted by Newcastle University ethics board and 
the Joint Ethics Committee of Newcastle and North Tyneside Health Authority (ref: 
08/H0906/136). DLB and AD subjects had been part of several prospective clinical 
studies, and had received detailed clinical assessments and case note review after 
death. Neuropathological assessment was performed according to standardized 
neuropathological diagnostic procedures (31-35). Clinical and pathological data was 
collated to establish a clinico-pathological consensus diagnosis. 
Three groups of cases were included in the present study: DLB cases that had 
experienced complex visual hallucinations during life, AD cases that had not 
experienced visual hallucinations during life and clinically confirmed aged control 
cases that showed none, or only low, age-associated neurodegenerative pathology 
at post-mortem examination.  
At autopsy, the right hemisphere was fixed in 10% formalin and cut into 7 mm 
coronal slices, prior to further dissection into blocks for neuropathological 
assessment. The pulvinar nucleus was identified by its location at the posterior 
portion of the thalamus, ending in the lateral ventricle (36).  Only cases containing 
the entire pulvinar were included for histological analyses, giving a group of eight 
control, eight DLB and eight AD cases. The pulvinar were exhaustively serially 
sectioned, with 30 μm and 10 μm sections obtained at each 1 mm interval. 30 μm 
sections were stained with cresyl fast violet for stereological analyses. 10 μm 
sections were stained with antibodies against a range of protein targets (Table 1) 
using Menarini Menapath Polymer detection kits (Menarini, Berkshire, UK), as per 
manufacturer’s instructions.  
 
Stereology 
The border of the anterior and medial pulvinar could not be reliably differentiated 
through coronal examination so these regions were thus grouped together for 
stereological analyses and will subsequently be referred to as the ‘anteromedial 
pulvinar’. The inferior pulvinar was incomplete in almost every case due to its 
location at a point where the midbrain is dissected from the diencephalon, thus 
precluding stereological analysis of this sub-region. The lateral pulvinar was 
differentiated from other structures based on its striated appearance (37). 
Stereological analysis was conducted using a Zeiss AxioVision Z.1 microscope 
equipped with a motorized stage (Zeiss, Oberkochen, Germany), coupled to a 
computer with Stereologer software (Bethesda, MA, USA).  
Stereological estimates were established in the anteromedial and lateral pulvinar 
nuclei based on (37) as shown in figure 1. Volumes were determined in the 
anteromedial and lateral pulvinar nuclei using Cavalieri’s principle and mean cell 
densities within each nucleus estimated using the optical disector method (38).  
Cavalieri’s principle was calculated by the following equation: 
𝑉 ≔ 𝑇 ∙ 𝑎 ∙ Σ𝑝 
Cavalieri’s principle allows estimation of the total volume of each region of interest 
per case based on the intersection distance (𝑇), the area per point (𝑎) and the sum 
of the number of counted points (𝑝). For estimation of volume, frames were placed in 
a uniform random manner, with disector frames spaced at 975 μm for anteromedial 
pulvinar, and 800 μm for lateral pulvinar, based on the relative size and distribution 
of the structures examined.  
The rater (D.E.) traced an outline around the region of interest (i.e. anteromedial or 
lateral pulvinar) using a 2.5x objective. Disector frames were placed in a uniform, 
random arrangement to calculate the density of cells within a defined region, using 
the following equation: 
𝑁𝑣 =
∑ 𝑄−𝑝−
𝑃 ⋅ 𝑉
 
Where 𝑁𝑣 = numerical density,  𝑝 − = disector samples, 𝑄− = Q-weighted number 
of objects counted, 𝑃 = total number of disectors, and 𝑉 = disector volume. 
Neuronal counts were conducted at 63x oil-immersion objective using the optical 
disector probe. Glial cell counts were calculated in both pulvinar sub-regions in 
disector frames of 3500 μm2, with neuron counts calculated in disector frames of 
1900 μm2. Section thickness did not vary across disease groups in anteromedial or 
lateral pulvinar. The mean coefficients of error (CE) for neuronal and glial cell 
estimates was calculated using the Gundersen-Jensen method (39), as illustrated by 
the following equation: 
𝐶𝐸2 = (
Σ (𝐼2)
(Σ 𝐼)2
+
Σ (𝑉𝑜𝑙𝑢𝑚𝑒2)
Σ (𝑉𝑜𝑙𝑢𝑚𝑒2)
−
2Σ(1 ⋅ 𝑉𝑜𝑙𝑢𝑚𝑒)
(Σ 𝐼 ⋅ Σ 𝑉𝑜𝑙𝑢𝑚𝑒)
) ⋅ (
𝑛
𝑛 − 1
) 
Where 𝐼 = neurons counted, 𝑉𝑜𝑙𝑢𝑚𝑒 = reference area x (sampling frame density)2 
x section depth, and 𝑛 = number of fields. 
Using the Gundersen-Jensen method (39), mean coefficient of error (CE) values for 
all stereologically-obtained data showed acceptable levels of accuracy (<0.10), with 
error values contributing less than 50% of the total observed coefficient of variance 
(CV). These values are considered to have acceptable levels of accuracy for 
stereological estimates (40).  
 
Neuropathology  
The anterior, medial and lateral nuclei of the pulvinar were analyzed using 
quantitative neuropathological techniques. Although the anterior and medial pulvinar 
border could not be discerned reliably for stereological analysis, where the entire 
structure along its antero-posterior extent is required, it was possible to identify the 
individual structures for analysis of neuropathology using one section per structure. 
For analysis of the anterior pulvinar, the section which contained the emergence of 
the anterior pole of the pulvinar was used. The medial and lateral pulvinar nuclei 
were defined as the region at which both structures were at their maximal area on 
coronal section, as in (41).  
To quantify neuropathological lesions, images of the sub-nuclei of the pulvinar were 
taken on a Zeiss AxioVision Z.1 microscope using a DsFi1 camera (Nikon, Tokyo, 
Japan). Stereologer software was used to delineate a region of interest with a 2.5x 
objective, prior to placement of disector frames in a uniform, random arrangement. 
This method prevented the introduction of bias by giving every area of the region of 
interest an equal probability of being sampled for analysis. Disector frame sizes were 
determined based on the size of the measured particles and their distribution across 
the region of interest. In all cases, amyloid-β and tau were measured using 10x 
objective and α-synuclein, CD68 and glial fibrillary acidic protein (GFAP) were 
measured using 20x objective. Images were taken within the disector frames and 
analyzed using ImagePro Plus v.4.1 image analysis system (Media Cybernetics, 
Bethesda, MA, USA). Using previously published techniques (18, 42), the mean 
percentage area of immunopositivity was determined by standardizing red-green-
blue (RGB) thresholds per antibody and applying to all sections per case. Each case 
thus had a mean value generated per antibody across all sections analyzed.  
 
  
RESULTS 
Demographics 
No significant difference was found between groups in terms of age at death 
(p=0.63) or post-mortem delay (p=0.43; Table 2).  
Final MMSE scores were available for 14/24 cases (five control, five DLB, four AD) 
and there was no significant difference between groups in the interval from last 
assessment to death (p=0.36). MMSE scores were significantly reduced in DLB 
(p<0.01) and AD (p<0.01) cases compared to controls, but there was no significant 
difference between AD and DLB (Table 2).  
 
Stereology  
In the anteromedial pulvinar, no significant main effect of diagnosis on neuronal 
(F=3.02, p=0.07) or glial number (F=1.00, p=0.39) was found, and the volume of the 
structure was not significantly different across groups (F=1.27, p=0.30; figure 2).  
In the lateral pulvinar, a significant main effect of diagnosis on neuronal number was 
found (F=14.219, p<0.01). Post-hoc tests using Tukey’s HSD showed a significant 
mean 30.7% decrease in neuronal number in DLB cases compared to controls 
(p<0.01) and a significant (16.7%) decrease in AD cases compared to controls 
(p=0.02). Despite DLB cases showing a greater degree of neuronal loss than AD 
cases, the differences were not statistically significant (p=0.06). No significant 
differences in glial cell number (F=0.125, p=0.88) or lateral pulvinar volume (F=2.45, 
p=0.11) were found across groups (figure 2).  
 
Neuropathology 
α-synuclein was significantly higher in DLB cases in all three regions analyzed 
compared to control and AD cases (fig. 3). In DLB cases, the medial pulvinar was, 
invariably, more severely affected by α-synuclein pathology than the lateral (p=0.01) 
or anterior nuclei (p=0.05), and no significant difference in expression was found 
between anterior and lateral nuclei (fig. 4). Again as expected, amyloid-β and tau 
pathology were significantly higher in AD cases when compared to control cases (fig. 
3).  
No significant differences were found between groups in the microglial marker CD68 
in any pulvinar sub-region (data not shown). GFAP, a marker of astrocytes, was 
significantly increased in DLB and AD cases in all pulvinar sub-regions compared to 
control cases. However, there was no significant difference in GFAP expression 
between DLB and AD cases in any sub-region. There was a 47.3% increase 
(p=0.01) in DLB cases and a 57.2% increase (p<0.01) in AD cases compared to 
control in GFAP expression in the anterior pulvinar. There was a 46.9% increase 
(p=0.04) in DLB cases and a 56.6% increase (p<0.01) in AD cases compared to 
control in GFAP expression in the medial pulvinar. There was a 37.6% increase 
(p=0.05) in DLB cases and a 46.9% increase (p=0.01) in AD cases compared to 
control in GFAP expression in the lateral pulvinar. 
 
  
DISCUSSION 
The present study found a significant loss in the number of neurons in the lateral, but 
not anteromedial, pulvinar of DLB cases with visual hallucinations compared to 
controls. The lateral pulvinar of AD cases also showed a significant reduction in 
neuron number when compared to control cases and, whilst this reduction was less 
than that found between DLB and control cases, there was no significant difference 
between DLB and AD. Lewy body pathology and increased astrocyte 
immunoreactivity was also found in the pulvinar in DLB against control cases, but no 
significant difference in astrocyte expression was found in DLB compared to AD 
cases.  
A previous study has shown the pulvinar is vulnerable to Lewy body pathology, in 
comparison to other visual regions of the thalamus, such as the LGN (30). This is in 
broad agreement with the findings outlined in this study, as well as our previous 
study in the LGN (18). Here, we extend these findings by demonstrating a specific 
pattern of neuronal loss in the lateral pulvinar, with the findings of no change in 
neuronal number in the anteromedial pulvinar mirroring our previous findings in the 
LGN. In contrast, AD cases had significant neuronal loss in the LGN (18) and less 
marked neuronal losses in the lateral pulvinar when compared to DLB. Taken 
together, these findings suggest that neuronal loss in the visual thalamus in DLB is 
specific to the lateral pulvinar, where neuronal loss is more severe than that 
observed in AD. This is an interesting finding as stereological studies conducted in 
regions outside of the mid-brain do not usually find neuronal reductions in DLB that 
exceed those in AD (for a review see (43)). Our findings may therefore indicate that 
the severe and specific neuronal loss in the lateral pulvinar in DLB may contribute to 
differences in the clinical phenotypes between DLB and AD. 
The lateral pulvinar is known to receive predominant innervation from visual cortical 
areas (44) and to be functionally involved in regulating cortical activity in vision-
related pathways (45). As the lateral pulvinar has been shown to have a strong 
regulatory influence on the functioning of the primary visual cortex (46), its 
degeneration in DLB may lead to altered functioning of the visual cortex, which, in 
turn, may contribute to hallucinogenesis. In primate visual area V4, deactivation of 
the lateral pulvinar leads to reduced frequency of cortical oscillations similar to those 
observed during inattention or sleep (21). Additional lesion studies of the lateral 
pulvinar in non-human primates have demonstrated behavioral changes indicative of 
perceptual neglect, such as reluctance to grasp target stimuli with the contralateral 
limb (47), indicating a role in visual attention. As impaired visual attentional function 
is thought to contribute to the manifestation of visual hallucinations in DLB (12, 20), 
the neuronal loss observed in the lateral pulvinar may relate to the occurrence of 
visual hallucinations through visual attentional impairment.    
The medial pulvinar, which possessed the greatest α-synuclein pathology among the 
pulvinar nuclei examined in DLB cases (fig. 4), has been shown in non-human 
primates to have substantial reciprocal connectivity with regions known to be 
vulnerable to α-synuclein pathology, including the amygdala and cingulate gyrus 
(48). This is in contrast to the lateral pulvinar, which has greater connectivity with 
early visual cortical areas (22), which are often unaffected by Lewy body pathology 
in DLB (49). Similarly, the anterior pulvinar is substantially connected with the 
somatosensory cortex (50), which is only affected at late stages of Lewy body 
pathology (51). Considering the emerging view suggesting α-synuclein pathology 
may spread in a manner reminiscent of prion protein (52, 53), it is perhaps 
unsurprising that greater Lewy body pathology is observed in regions that are 
connected to sites severely affected and at early stages in the progression of DLB. 
However, it is possibly more surprising that the medial pulvinar did not exhibit 
neuronal loss in DLB, considering its higher burden of α-synuclein pathology. One 
possible explanation is that neuronal loss is the result of reduced input from regions 
that project to the lateral pulvinar, with reductions occurring over time as a result of 
diminished input.  
Previous neuroimaging findings have shown that DLB cases have reduced grey 
matter density, as measured by mean diffusivity, in posterior thalamic regions that 
project to occipital and parietal regions (28). While the cytoarchitectonic parcellation 
of the pulvinar into anterior, medial, lateral and inferior sub-regions is not fully 
compatible with its segregation based on its physiology and connectivity (27), areas 
corresponding to the lateral pulvinar have been shown to project to occipital and 
parietal regions (44, 54). Hence our finding of neuronal loss in the lateral pulvinar 
corroborates neuroimaging studies by providing a neuropathological correlate for 
reduced grey matter density (28). Changes in mean diffusivity on neuroimaging have 
also been demonstrated to relate to clinical markers of visual hallucination frequency 
and severity, suggesting a relationship between degeneration of pulvinar sub-nuclei 
that project to occipital regions and the occurrence of visual hallucinations (28).  
The specific pattern of neuronal loss seen in the lateral pulvinar in DLB patients has 
also been demonstrated in stereological studies of schizophrenic patients (55). 
Although visual hallucinations are relatively uncommon in schizophrenia (56), 
schizophrenic and DLB patients have visual attentional deficits (9, 57) and 
impairments in smooth pursuit eye movements (9, 58), which can occur as a result of 
attentional dysfunction (59). Considering the putative role of the lateral pulvinar in 
modulating visual cortical activity based on attentional demands (21, 45, 46), these 
findings may highlight a common degenerative change that promotes visual 
attentional dysfunction in both disorders. In DLB, visual attentional deficits may act in 
concert with dysfunction or degeneration of other brain regions to elicit 
hallucinations.   
In summary, we have shown specific patterns of degeneration in the pulvinar of DLB 
cases and that these degenerative changes are more severe in DLB compared to 
AD. The putative role of the lateral pulvinar in modifying the response properties of 
visual cortical neurons based on attentional demands might suggest that lateral 
pulvinar degeneration contributes to deficient visual attentional mechanisms and 
corresponding cortical activity changes, which have both previously been related to 
visual hallucinations in DLB (12, 60). The results of our current study support 
neuroimaging findings associating the degeneration of particular pulvinar sub-
regions with visual hallucinations in DLB (28). However, it should be noted that the 
pulvinar is one component in a highly complex and incompletely understood system 
and is therefore likely to act in concert with other regions to contribute to the 
occurrence of visual hallucinations. Hence, continued study of the vulnerability of the 
visual system is warranted to further our understanding of the pathological changes 
that promote visual hallucinations in DLB. 
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TABLES AND LEGENDS 
Table 1: Antibody dilutions. 
Antibody Manufacturer Dilution Antigen retrieval 
GAD65/67 
4G8 amyloid-β 
AT8 phosphorylated-τ 
5G4 α-synuclein 
Sigma 
Covance 
Autogen 
Analytik Jena 
1:6000 
1:15,000 
1:10,000 
1:4500 
Citrate pH 6 
Formic acid 
Citrate pH 6 
Citrate pH 6 + formic 
acid 
 
Table 2: Demographic characteristics of cohort. ‘Age’ refers to age at death, ‘PM 
delay’ refers to the delay between death and post-mortem examination, ‘Braak NFT’ 
stage is neurofibrillary pathology stage outlined in (61), ‘Thal phase’ is amyloid-β 
pathology stage as outlined in (33), ‘McKeith Lewy body stage’ is Lewy body 
pathology stage outlined in (32), ‘MMSE’ is mini-mental state examination score, 
‘NA’ represents data not being available.    
Case ID Age PM delay Diagnosis Braak NFT 
stage 
Thal 
phase 
McKeith 
Lewy body 
stage 
Final 
MMSE 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
99 
77 
85 
80 
65 
73 
76 
78 
73 
81 
89 
77 
81 
78 
91 
73 
81 
89 
68 
85 
76 
86 
95 
85 
5 
83 
57 
16 
47 
25 
86 
23 
99 
81 
88 
46 
44 
96 
10 
47 
73 
61 
24 
32 
6 
123 
23 
39 
Control 
Control 
Control 
Control 
Control 
Control 
Control 
Control 
DLB 
DLB 
DLB 
DLB 
DLB 
DLB 
DLB 
DLB 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
AD 
2 
2 
3 
2 
1 
0 
2 
2 
3 
3 
3 
3 
4 
3 
3 
3 
5 
6 
6 
5 
6 
6 
6 
6 
0 
3 
4 
0 
0 
0 
1 
1 
4 
4 
2 
0 
3 
3 
4 
1 
5 
5 
5 
5 
5 
5 
5 
4 
None 
None 
None 
Brainstem 
None 
None 
Amygdala 
None 
Neocortical 
Neocortical 
Neocortical 
Neocortical 
Neocortical 
Neocortical 
Neocortical 
Neocortical 
None 
None 
None 
None 
None 
Brainstem 
Amygdala 
None 
27 
NA 
29 
29 
NA 
30 
30 
NA 
13 
NA 
14 
12 
NA 
9 
NA 
22 
NA 
18 
NA 
15 
6 
NA 
NA 
19 
 
 FIGURES AND LEGENDS 
Figure 1: The anatomy of the pulvinar. The anteromedial (dashes) and lateral (dots) 
pulvinar nuclei are shown. Scale bar = 3 mm.  
Figure 2: Stereological estimates of number and volume in the pulvinar nuclei. 
*p<0.05, **p<0.01. 
Figure 3: Quantitative neuropathology in the pulvinar sub-nuclei. *p<0.05 compared 
to control; **p<0.05 compared to control and DLB; ***p<0.05 compared to control 
and AD.  
Figure 4: α-synuclein pathology in the pulvinar sub-nuclei. Representative 5G4 
staining in the (A) anterior, (B) lateral and (C) medial pulvinar of a DLB case. Scale 
bar = 50 μm. 
 
 
 
 
